Oriflame Cosmetics announces its 2012 Nomination Committee, whose tasks include providing proposals regarding the composition of Oriflame's board of directors to the 2012 Annual General Meeting

Michelle Rivera

Michelle Rivera

MALMÖ, Sweden , December 19, 2011 (press release) – The Nomination Committee, whose tasks include providing proposals regarding the composition of Oriflame’s (STO:ORISDB) Board of Directors to the 2012 Annual General Meeting, comprises:

Robert af Jochnick, representing the af Jochnick family

Carlos Hardenberg, Franklin Templeton Investments

Per Hesselmark, Stichting af Jochnick Foundation

Damien Lanternier, Financière de l'Échiquier

Åsa Nisell, Swedbank Robur Funds

Shareholders who wish to contact the Nomination Committee can do so by e-mail to corporate.governance@oriflame.com

Oriflame Cosmetics is an international beauty company selling direct. The company began operations in 1967 in Sweden and has today a presence in over 60 countries worldwide. Oriflame offers a wide portfolio of Swedish, natural, innovative, quality beauty products at affordable prices. To-date Oriflame has over 3.5 million consultants worldwide with annual sales of €1.5 billion. Oriflame offers the leading business opportunity for people who want to start making money the same day they join and then grow into a leadership role and fulfil their personal dreams and ambitions. Oriflame is listed on NASDAQ OMX Stockholm since 2004.


BW-image© 2024 Business Wire, Inc., All rights reserved.

Share:

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.